Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products. The company provides healthcare solutions that address the evolving needs of patients and societies worldwide. The company’s portfolio includes medicines, eye care products, and generic pharmaceuticals. Divisions The company’s divisions include Pharmaceuticals, Alcon, and Sandoz. Pharmaceuticals division This division offers patent-protected medicines to patients and physicians. This division researches, develops, manufactures, distributes and sells patented pharmaceuticals in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. Products Oncology Gleevec/Glivec (imatinib mesylate/imatinib) is a kinase inhibitor approved to treat patients with metastatic and/or unresectable KIT (CD117) positive (KIT+) gastrointestinal stromal tumors (GIST), as an adjuvant treatment for certain adult patients following resection of KIT+ GIST, and as a targeted therapy for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia. Gleevec/Glivec is available in approximately 120 countries. Gleevec/Glivec is also approved in the United States (U.S.) and the European Union (EU) to treat dermatofibrosarcoma protuberans, a rare solid tumor; hypereosinophilic syndrome; and myelodysplastic/myeloproliferative diseases and other rare blood disorders. In the U.S., Gleevec is also approved for aggressive systemic mastocytosis. Gleevec/Glivec has received approvals in approximately 65 countries as a post-surgery (adjuvant setting) therapy for certain adult patients with KIT+ GIST. Afinitor/Votubia and Afinitor Disperz/Votubia dispersible tablets (everolimus) is an oral inhibitor of the mTOR pathway. Afinitor is approved in approximately 120 countries, including the U.S., the EU member states, and Japan for advanced renal cell carcinoma following vascular endothelial growth factor-targeted therapy (in the U.S., after failure of sunitinib or sorafenib). Afinitor is also approved in 95 countries, including the U.S., the EU member states, and Japan for the treatment of advanced pancreatic neuroendocrine tumors. In addition, Afinitor is approved in 100 countries for advanced hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer in combination with the drug exemestane. Everolimus is also approved in approximately 95 countries, including in the U.S. as Afinitor and in the EU as Votubia to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC); and in 90 countries for the treatment of adult patients with renal angiomyolipomas and TSC who do not require immediate surgery. Afinitor Disperz, the dispersible tablet for oral suspension formulation of Afinitor, is approved for the TSC-SEGA population in various countries, including the U.S. and Japan. Votubia dispersible tablets are approved for the treatment of patients with TSC-SEGA in the EU member states. Everolimus, the active ingredient in Afinitor, is also available under the trade names Zortress/Certican for use in transplantation in the U.S. and EU, respectively, and is licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents. Tasigna (nilotinib) is a signal transduction inhibitor of the BCR-ABL tyrosine kinase. Tasigna is approved in approximately 110 countries to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic and/or accelerated phase who are resistant or intolerant to existing treatment, including Gleevec/Glivec. It is also approved in approximately 85 markets, including the U.S., the EU member states, Switzerland, and Japan, to treat newly diagnosed patients in the chronic phase. Sandostatin SC and Sandostatin LAR (octreotide acetate/octreotide acetate for injectable suspension) is a somatostatin analogue indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients
novartis ag-sponsored adr (NVS:New York)
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01www.novartis.com
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for NVS.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.